Anecdotal evidence suggesting a causal relationship between psychiatric illness, environmental stress and a malfunctioning immune system goes back to antiquity. Recently, clinical and experimental studies have established the interrelationship between neuroendocrine regulation, the immune system and abnormalities in central neurotransmission which may be deranged as a consequence of stressful events. This short review is an attempt to assess the evidence implicating altered immune responsiveness in depression and to consider the impact of different types of environmental stress in triggering the immune malfunction. While these findings are of considerable biological importance, it is presently unclear whether the immunological changes are primary or secondary to the disease states. Solomon, 1987; Cotman et al., 1987; Singh and Fudenberg, 1986; Schmidler, 1985). It is well known that, in addition to subtle cell-cell interactions and cellular specificity, only the central nervous and the immune systems possess a cellular memory and a well-developed network of communication which is operated by neurotransmitters and lymphokines, the so-called immunotransmitters. In addition to the bidirectional interactions between the brain and the endocrine system, and between the endocrine and immune system, it has also been shown that the central nervous system can interact directly with the immune system. Singh and Fudenberg (1986) have summarized the similarities between the cells of the immune system, the immunocytes, and cells of the central nervous system. Abstract Holmes W L 1964 Effect of chlorpromazine as prostaglandin synthesis in rat brain In Lipid pharmacology (ed Paoletti R) New York pp 131-135 Horrobin D F, Manku M S, Mtabaji J P 1977 A new mechanism of tricyclic antidepressant action. Blockade of prostaglandin-dependent calcium movements. Postgraduate
The role of the brain as a potential modulator of disease was first recognized by Galen some 200 years ago who hypothesized that women with a melancholic temperament were more prone to cancer than those of sanguine temperament.
Since that time, numerous anecdotal reports have appeared to support the view that psychiatric illness can predispose the patient to lifethreatening infections and cancers. Indeed, over a century ago the great physician Sir William Osler pointed out that to predict the outcome of a tuberculosis infection it was more important to understand what was going on in a man's head than in his chest! Despite the widely accepted clinical practice of the need to consider the whole body rather than merely to treat the diseased organ in order to ensure an optimal response to treatment, it is only in the last 25 years that serious consideration has been given to the bidirectional interactions between the brain and the immune system. The first attempts to lay a scientific basis to psychoneuroimmunology was due to Ader (1961) and Solomon and Moos (1964) , and served to stress that all disease is multifactorial, and often resulting from a complex interrelationship between specific aetiological, genetic, endocrine, nervous, immune, emotional and behavioural factors. It is therefore self-evident that the psychopharmacologist must now be aware not only of the neurochemical, endocrinological and behavioural effects of a psychotropic drug, but also what action it may have on the immune system which may contribute to its clinical profile. It is not the purpose of this article to comment on the detailed nature of the interconnections between the brain, endocrine and immune systems which have been the subject of several detailed monographs and reviews (see These investigators emphasized the functional importance of such factors as the presence of S100 brain protein in both immunocytes and neurons, and the production of the interleukin-1 (IL-1) lymphokine by monocytes and astrocytes. Singh and Fundenberg (1986) cite the evidence to show that IL-1 has a potent mitogenic effect on the proliferation of astroglia whereas such sensory neuropeptides as substance P and somatostatin have been shown to modulate the functions of monocytes, at least in vitro. Both neurons and immunocytes contain neurotransmitter receptor (for example, acetylcholine, dopamine, serotonin and noradrenaline) and specific neuropeptide receptors (for example, the endorphins, somatostatin, substance P), the information from the transmitterreceptor interactions being mediated by K+, Na+ and Ca2+ ion channels. Peripheral-type benodiazepine binding sites have also been detected on human lymphocytes and glial cells (Moingeon et al., 1983) . While the precise function of such binding sites is presently unclear, there is evidence that minor tranquillizers can inhibit cellular mitogenesis (Clarke and Ryan, 1980) and may play a role in modulating cell differentiation (Matthew et al., 1981) . Clearly there is an area that needs further research by psychopharmacologists.
Neuropeptides and the immune system Moldofsky et al. (1984) have shown that IL-1 can enhance slow wave sleep in humans, while Tobler et al. (1984) reported that a similar phenomenon occurred in rats. Other studies have suggested that sleep-inducing peptides, such as the murmyl peptides (Ashmarin and Doredora, 1980) and factors (Kramarova et al., 1983) can modulate the immune system. More recently, Yehuda, Shredny and Kalechman (1987) showed that, in rats, the delta-sleep-inducing peptide induced initially a reduction followed by an elevation of IL-1 in the cerebrospinal fluid; the lymphokines IL-2 and IL-3 were reduced. While there is experimental evidence to suggest that some of the effects of this sleep peptide could be mediated by the serotonergic system which is known to induce immunological changes (Livnat et al.,, 1985) , it would appear from the studies of Yehuda, Shredny and Kalechman (1987) that the changes in the central lymphokines preceded the change in the sleep architecture and could not be explained by an altered activity of the serotonergic system.
Several studies have demonstrated that opioid peptides modulate immune functions (Teschemacher and Schweigerer, 1985) , such effects of the opioids generally being mediated through prostaglandin release. Thus Brown and Van Epps (1985) found that opioid-induced chemotaxis is inhibited by indomethacin, a potent prostaglandin synthetase inhibitor. Both betaendorphin and methionine-enkephalin have been shown to increase natural killer cell activity (Kay, Allen and Morley, 1984) , the natural killer cells playing an important role as cytotoxic agents that mediate the host defence to infections and in resistance to malignant cells. Doses of methionine-enkaphalin as low as 10-' mg/ml blood have been reported by Plotnikof et al. (1986) to stimulate the activity of both T and natural killer cells in normal human volunteers. Furthermore, the potency of the various endorphins differ, destyrosine endorphin being more potent than either the gamma-or beta-endorphins. The natural killer cell stimulatory activity of the endorphins is inhibited by the opioid antagonist naloxone (Morley et al., 1985) .
Other studies by Kay, Allen and Morley (1984) and Morley et al. (1985) showed that beta-endorphin and IL-2 had a synergistic effect on natural killer cell activity, an effect which could be blocked by naloxone. The possible connection between these effects of the endorphins and the immune system could arise as a consequence of the release of pituitary beta-endorphin in response to stress in which IL-2 causes the release of alpha-interferon which then stimulates the release of beta-endorphin. It must be emphasized that many of the studies suggesting that opioid peptides can enhance natural killer cell activity are based on in vitro or acute in vivo observations. Subchronic studies in rats subject to intermittent or continuous footshock stress on several occasions daily for four days, showed that natural killer cell activity was suppressed following the intermittent footshock (during which opioids were released) but not du;ing continuous footshock which does not appear to elicit the release of endogenous opioids (Shavit et al., 1984) . The opioid antagonist naloxone was shown to block the immune effects of the intermittent but not the continuous stress which supports the view that the suppression of the immune system by chronic stress may be mediated, at least in part, by endogenous opioids.
Neurotransmitters and the immune system Several neurotransmitter systems have been suggested as modulating the immune system, both within the CNS and in the autonomic nervous system. A brief overview only will be presented here. Those interested in a more extensive account are referred to articles by Hall and Goldstein (1981) and Felten and Overhage (1981) .
Serotonin ' While the direct effects of serotonin upon the immune system have not been systematically investigated, indirect evidence suggests that serotonin exerts a net inhibitory influence over immunogenesis. This conclusion is based on the investigation of Devoino and Eremina (1970) and Idova and Devoino (1972) who demonstrated that an inverse relationship exists between brain serotonin concentrations and antibody synthesis.
Dopamine
The central dopaminergic system appears to exert a net stimulatory influence over the immune system, a conclusion that is based on changes in the immune system of patients suffering from such neurological diseases as Parkinsonism (Fujiwara, Murgobayashi and Kitamura, 1976).
Noradrenaline and adrenaline
Both of these catecholamines have been implicated as immunomodulators, most of the evidence suggesting that their effects are modulated by changes in the autonomic nervous system. Thus adrenergic fibres have been identified in the interlobular septa of the rat thymus (Fujiwara, Murgobayashi and Kitamura, 1976) while during the course of the immune response the spleen concentration of noradrenaline has been shown to decrease significantly (Besodovsky and Sorkin, 1977) . Although changes in the vasculature might be associated with the alterations in the catecholamines, the presence of physiologically active beta-adrenoceptors on T-cells, B-cells and macrophages (Bourne and Lichtenstein, 1974) suggests that these catechol-amines may exert a direct effect on the immune system. Acetylcholine Several investigators have reported the presence of acetylcholine receptors in thymus tissue (Lindstrom and Lennon, 1976; Engel and Trotter, 1977) while Singh and Owen (1976) have suggested that nicotinic receptors occur on thymocytes. Cholinergic stimulation has been shown to stimulate the formation of cyclic GMP in such cells which can result in lymphocyte activation (Bourne and Lichtenstein, 1974) .
Opioids
Exposure to stress can cause the release of opioid peptides from both central and peripheral sites and there is considerable experimental evidence to suggest that the opioids can alter the percentage of T cells forming active rosettes, the reactivity of T cells to mitogenic stimulation and the cytotoxic activity of natural killer cells (Singh and Owen, 1976) . In addition to these effects of opioids on the immune system which have been observed in vivo and or in vitro, opioid receptors have been identified on granulocytes, monocytes, lymphocytes and the terminal complexes of complement (Shavit et al., 1984) . While the precise mechanism whereby endogenous opioid peptides mediate the suppression on natural killer cell activity is unclear, Shavit et al. (1984) have hypothesized that this may occur due to a suppression of interferon which normally induces and augments natural killer cell activity.
The effects of a number of neurotransmitters on the cellular components of the immune response are summarized in Table 1 .
Antidepressants on the immune system Severe damage to tissues has an immunosuppressive effect which may be of clinical importance. In the human, surgical trauma has been found to cause depression of the primary antibody response (Alexander and Montcrieff, 1966) and inhibition of the migration of lymphocytes and monocytes into inflamed areas (McCabe et al., 1973) . When the lymphocytes are removed from such patients, a depressed mitotic response to plant lectins and allogenic cells has been reported (Slade et al., 1975) together with an inhibition of the release of leu- (1986) have reported that lymphocytes obtained from untreated depressed patients who were not suffering from any apparent physical illness also showed a marked suppression of the mitogenic response to plant lectins.
It is well established that physical trauma in man is followed by an increase in serum cortisol and catecholamines (Jaattela et al., 1975) and is accompanied by the release of prostaglandins of the E series from the damaged tissues (Arturson, Hanburg and Jonsson, 1972) . These substances depress the mitogenic response of the lymphocytes to the plant lectin phytohaemagglutinin (Mendelsohn, Multer and Boone, 1973) . It may therefore be hypothesized that the decreased mitogenic responsiveness is attributable to the rise in prostaglandins, catecholamines and cortisol. However, there is no evidence to suggest that the rise in serum cortisol is responsible for the depressed mitogenic response following either physical trauma (Berenbaum, Fluck and Hurst, 1973) or in the depressed patient (Kronfol et al., 1986) , and while the possible involvement of increased circulating catecholamines cannot be completely excluded, in vitro studies suggest that their primary role is unlikely (Leonard, unpublished) . The most rational explanation therefore rests with the observation that prostaglandins of the E series are primarily responsible for the inhibition of at least part of the immune response following both physical injury and depression.
It has been known for some 14 years that prostaglandins El and E2 (PGE1 and E2) when administered intracerebroventricularly depress brain function (Coecani and Pace-Asciak, 1976 ). Furthermore, the inhibition or stimulation of central PG synthesis could be related to some of the psychotropic properties of drugs such as chloropromazine (Holmes, 1964) and the tricyclic antidepressants such as clomipramine (Horrobin, Manku and Mtabaji, 1977) . In vitro, Bekemeier, Giessler and Vogel (1977) have shown that monoamine oxidase inhibitors (MAOIs) inhibit, while morphine and chlorpromazine facilitate, the synthesis of PGs in the rabbit brain; lithium has been shown to inhibit the increased prostaglandin synthesis caused by prolactin and vasopressin without altering the basal synthesis (Horrobin, Mtabaji and Manki, 1976) . As there is evidence that both PGE2 and thromboxane A2 concentrations are markedly elevated in the serum of untreated depressed patients (Calabrese et al., 1986), it may be speculated that the prostaglandins may contribute not only the suppressed immune response found in the depressed patient, but also to the abnormalities in central neurotransmission which has been implicated in depression.
In addition to subnormal mitogenic response to plant lectins shown in depressed patients (Kronfol et al., 1986) , there is also evidence to suggest that the phagocytosis response of polymorph leucocytes is significantly reduced in the untreated depressed patient (O'Neill and Leonard, 1986 ) ; this would appear to be a state marker as the phagocytosis response normalizes following effective antidepressant treatment but does not change in those patients failing to respond to such treatment. Preliminary studies suggest that this abnormal response occurs in patients with panic attack but not in schizo-phrenics, alcoholics, dements or in patients with a generalized anxiety disorder (O'Neill et al., in preparaion) . Phagocytosis is markedly depressed by low concentrations of PGE2 in vitro and can be enhanced by aspirin in vivo (O'Neill and Leonard, 1990) . While such findings are preliminary, and by no means conclusive, they do support the hypothesis that antidepressants can act as central, and peripheral, prostaglandin synthetase inhibitors at therapeutically relevant concentrations. Such activity may contribute to their clinical effects. It is not without interest that the brain concentrations of prostaglandin synthetase inhibitors such as aspirin and indomethacin only produce a 10-20% inhibition of this enzyme at therapeutically relevant concentrations (Manku and Horrobin, 1976) . Presumably the enhanced lipophilicity of the tricyclic antidepressants, combined with their central prostaglandin synthetase inhibitor activity, therefore contribute to their therapeutic effects. Clearly the hypothesis linking the defective immune system and central neurotransmission with the symptoms of depression and the mode of action of antidepressant drugs is speculative and requires a thorough investigation of the effects of the various classes of antidepressant drugs, and ECT, on the immune responsiveness and prostenoid concentrations of depressed patients before it can be validated. Nevertheless, this hypothesis may help to point the way not only to new areas where psychotropic drugs may exert their actions but also towards a better understanding of how a disorganized immune system may contribute to a disordered mental state. Clearly the psychopharmacologist has a major role to play in the new and exciting field of psychoneuroimmuno- 
